NASDAQ: DRMADermata Therapeutics Inc Stock
$0.73+0.02 (+2.82%)
Updated Apr 17, 2025
DRMA Price
$0.73
Fair Value Price
$2.07
Market Cap
$3.96M
52 Week Low
$0.70
52 Week High
$6.17
P/E
-0.09x
P/B
2.54x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$12.29M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
1.26
Operating Cash Flow
-$11M
Beta
0.5
Next Earnings
May 7, 2025
Ex-Dividend
N/A
Next Dividend
N/A
DRMA Overview
Dermata Therapeutics, Inc. is a clinical-stage biotechnology company developing and commercializing treatments for medical and aesthetic skin conditions. Its lead candidates are DMT310 and DMT410. Known as Dermata Therapeutics, LLC until 2021, the company was founded in 2014 and is headquartered in San Diego, CA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine DRMA's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
F
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
DRMA
Ranked#258 of 463
Ranked#258 of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.61 | A | |
| $7.75 | A | |
| $16.85 | A |
Be the first to know about important DRMA news, forecast changes, insider trades & much more!
DRMA News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how DRMA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
DRMA ($0.73) is undervalued by 64.73% relative to our estimate of its Fair Value price of $2.07 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
DRMA ($0.73) is significantly undervalued by 64.73% relative to our estimate of its Fair Value price of $2.07 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
DRMA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more DRMA due diligence checks available for Premium users.
Valuation
DRMA fair value
Fair Value of DRMA stock based on Discounted Cash Flow (DCF)
Price
$0.73
Fair Value
$2.07
Undervalued by
64.68%
DRMA ($0.73) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
DRMA ($0.73) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
DRMA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
DRMA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.09x
Industry
-177.72x
Market
27.98x
DRMA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.54x
Industry
4.05x
DRMA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
DRMA's financial health
Profit margin
Revenue
$0.0
Net Income
-$3.2M
Profit Margin
0%
Assets to liabilities
Assets
$3.5M
Liabilities
$2.0M
Debt to equity
1.26
DRMA's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
DRMA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.9M
Investing
$0.0
Financing
-$68.6k
DRMA vs Biotech Stocks
Dermata Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.